Welcome to our dedicated page for Theravance Bioph news (Ticker: TBPH), a resource for investors and traders seeking the latest updates and insights on Theravance Bioph stock.
Theravance Biopharma Inc (NASDAQ: TBPH) drives innovation in organ-selective medicines, with this dedicated news hub providing essential updates for stakeholders. Access verified press releases and objective reporting on clinical developments, regulatory milestones, and strategic partnerships.
This comprehensive resource delivers timely information about TBPH's respiratory therapies like YUPELRI® and emerging pipeline candidates. Track progress across key areas including COPD treatment advancements, neurological disorder research, and collaborative drug development initiatives.
Users can expect updates covering FDA submissions, clinical trial outcomes, financial results, and scientific publications. All content undergoes rigorous verification to ensure alignment with corporate disclosures and regulatory standards.
Bookmark this page for direct access to primary source materials and distilled insights into Theravance Biopharma's progress in biopharmaceutical innovation. Regularly refreshed content supports informed decision-making for investors and industry observers.
Theravance Biopharma (NASDAQ: TBPH) has scheduled its first quarter 2025 financial results announcement and business update for Thursday, May 8, 2025, after market close. The company will host a conference call and simultaneous webcast at 5:00 pm EDT (2:00 pm PDT/10:00 pm IST) on the same day.
Participants can join via telephone by dialing (800) 715-9871 from the US or (646) 307-1963 internationally, using Conference ID 3369474. The webcast will be accessible through the Investors section of Theravance Biopharma's website and will remain available for replay until June 7, 2025.
Theravance Biopharma (NASDAQ: TBPH) presented new analyses of ampreloxetine, their investigational treatment for symptomatic neurogenic orthostatic hypotension (nOH), at the American Academy of Neurology 2025 Annual Meeting. The analyses from Phase 3 trials demonstrated the drug's selective mechanism and safety profile.
Key findings showed that patients on ampreloxetine experienced a 58% mean increase in venous plasma norepinephrine levels after 4 weeks, with MSA patients showing a 79% increase. The drug demonstrated sustained improvement in orthostatic blood pressure, particularly in MSA patients. Importantly, ampreloxetine showed no worsening of supine hypertension, a common side effect of current FDA-approved treatments that typically carry black-box warnings.
The data came from two Phase 3 trials (Study 0169 and 0170) involving patients with nOH in multiple system atrophy, Parkinson's Disease, and pure autonomic failure. These results support an ongoing registrational study (CYPRESS) in patients with nOH and MSA.
Theravance Biopharma (NASDAQ: TBPH) has announced its participation in the upcoming Jones Healthcare and Technology Innovation Conference in Las Vegas. The company will engage in a fireside chat on Wednesday, April 9 at 11:30 am PDT (2:30 pm EDT/6:30 PM GMT).
The company's senior management team will be available for one-on-one meetings during the conference. Interested parties can arrange meetings through their Jones representative or by contacting Yuki Gonzalez, Vice President of Marketing & Corporate Access.
A recording of the fireside chat will be made available on Theravance.com under the Investors section, Events and Presentations, and will remain accessible for 30 days following the event.
Theravance Biopharma (NASDAQ: TBPH) has announced new analyses of their Phase 3 ampreloxetine program for Neurogenic Orthostatic Hypotension (nOH) to be presented at the 77th Annual Meeting of the American Academy of Neurology (AAN) in San Diego from April 5-9, 2025.
The presentations, scheduled for April 7, 2025, will showcase findings from Studies 169 and 170, which led to the ongoing Phase 3 confirmatory CYPRESS Study 197 focusing on nOH in multiple system atrophy patients. Two key presentations will be delivered:
- NET-Inhibition with Ampreloxetine, Blood Pressure, and Catecholamines in nOH Patients
- The Impact of Ampreloxetine on Supine Hypertension: An Ambulatory Blood Pressure Monitoring Study
Theravance Biopharma (TBPH) reported strong Q4 and FY 2024 results, with YUPELRI achieving record US net sales of $66.7M in Q4 (up 10% YoY) and $238.6M for FY2024 (up 8% YoY). TRELEGY global net sales reached $3.46B in FY2024, up 26% YoY, triggering a $50M milestone payment to TBPH.
Q4 financial highlights include revenue of $18.8M from Viatris collaboration, R&D expenses of $9.5M, and SG&A expenses of $18.5M. The company ended Q4 with $88.4M in cash, excluding the $50M TRELEGY milestone received in February 2025.
For 2025 guidance, TBPH expects R&D expenses of $32-38M and SG&A expenses of $50-60M (excluding share-based compensation). The CYPRESS study for ampreloxetine remains on track to enroll its final patient by mid-2025.
Theravance Biopharma (NASDAQ: TBPH) has announced its participation in the TD Cowen 45th Annual Health Care Conference. The company's presentation is scheduled for Tuesday, March 4 at 11:50 am EST (8:50 am PST/4:50 pm GMT).
The company will engage in in-person meetings with the investment community during the conference. Investors and interested parties can access the webcast through the Investors section under Events and Presentations on Theravance.com. The webcast recording will remain available on the company's website for 30 days following the presentation.
Theravance Biopharma (NASDAQ: TBPH) has announced it will release its fourth quarter and full year 2024 financial results and business update after market close on February 26, 2025. The company will host a conference call and simultaneous webcast at 5:00 pm EST (2:00 pm PST/10:00 pm GMT) on the same day.
Interested participants can pre-register for the telephone conference call through the provided link. The webcast will be accessible through Theravance Biopharma's website under the Investors section, Events and Presentations. A replay of the webcast will remain available on the company's website for 30 days until March 28, 2025.
Theravance Biopharma (NASDAQ: TBPH) has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference. The presentation is scheduled for Wednesday, February 12 at 12:00 pm EST (9:00 am PST/5:00 pm GMT).
Investors and interested parties can access the webcast through the Investors section under Events and Presentations on Theravance.com. The webcast recording will remain available on the company's website for 30 days following the presentation.
Theravance Biopharma (NASDAQ: TBPH) has announced that its management team will be conducting investor meetings during the 43rd Annual J.P. Morgan Healthcare Conference. The conference is scheduled to take place from January 13-16, 2025, in San Francisco, CA. Interested investors can request one-on-one meetings with the management team by contacting the company's investor relations department.
Theravance Biopharma (NASDAQ: TBPH) has announced its participation in the 7th Annual Evercore HealthCONx Conference. The company will engage in a Fireside Chat on Tuesday, December 3 at 11:15 am EST, alongside hosting in-person meetings with the investment community. The event will be accessible via webcast on Theravance.com under the Investors section, with a replay available for 30 days following the presentation.